Product
Eureka
For R&D, Eureka makes reading and utilizing patents & technical documents easy.
Eureka AIR
Designed for self-driven R&D workflows. Generate viable solutions, solve complex R&D challenges, empower your innovation with AI.
Eureka Materials
Designed for material experts only. Revolutionize your material R&D, from search, analyze, to developing new materials.
Feature
TechResearch
Generate reliable direction feasibility study reports for your R&D in just a few steps.
TechSeek
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
TechMind
As an expert in R&D Theories, TechMind can generates customized viable solutions instantly.
TechRisk
Analyze your overall solution with one click, know your potential R&D risks in advance.
TechMonitor
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
99 results about "Pentacyclic triterpenoid" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Pentacyclic triterpenes are natural compounds which are widely distributed in plants. These natural products have been demonstrated to possess anti-inflammatory properties. Triterpenoids have been reported to possess antioxidant properties, since they prevent lipid peroxidation and suppress superoxide anion generation.
Anti-aging composition, kit and method of use
InactiveUS20070237735A1Reducing and preventing age-related skin symptomReducing and preventing symptomBiocideCosmetic preparationsMADECASSIC ACIDAntioxidant
An anti-aging composition comprising: (i) at least one biomimetic oligopeptide having a sequence of 20 amino acids or less; (ii) at least one lipoaminoacid; (iii) at least one pentacyclic triterpenoid selected from the group consisting of asiaticoside, madecassic acid, asiatic acid and madecassoside; (iv) at least one antioxidant; and (v) tetrahydropiperine; a kit comprising such composition and a method of use.
Owner:LABES DERMO COSMETIK
Pentacyclic triterpenoid cholesterol ester transfer protein (CETP) inhibitor, pharmaceutical composition thereof and medical application
The invention relates to the pharmaceutical field, in particular to application of a series of pentacyclic triterpenoid compounds as a cholesterol ester transfer protein (CETP) inhibitor, in particular to application in factors of preparing medicines for treating cardiovascular and cerebrovascular diseases, atherosclerosis diseases and hyperlipemia. The invention further discloses a series of novel pentacyclic triterpenoid compounds, application of the compounds as the CETP inhibitor and a pharmaceutical composition.
Owner:CHINA PHARM UNIV
Pentacyclic triterpene and melbine salt of derivative thereof, preparation method and medical application of pentacyclic triterpene
The invention relates to field of natural medicine and medicinal chemistry, in particular to novel pentacyclic triterpene and melbine salt I of the derivative thereof. The salt compound can be used for preparing medicaments curing diabetes mellitus and complicating disease thereof, cerebral ischemia, angiocardiopathy, atherosclerosis, hepatitis, fatty liver and metabolic syndrome or tumour, descendens blood fat drugs and anti-obesity drugs. The invention also relates to the preparation method of the salt compound.
Owner:CHINA PHARM UNIV
Medical use of pentacyclic triterpenoid saponin and pharmaceutical composition thereof
InactiveCN110200981AImprove securityGood curative effectOrganic active ingredientsSenses disorderBovine respiratory diseaseDiabetic complication
The present invention discloses an application of pentacyclic triterpenoid saponin represented by formulas (I) to (XIII) for the preparation of a medicine for preventing or treating AMPK-mediated diseases including fatty liver disease, inflammatory bowel disease, respiratory disease, diabetic complications and polycystic kidney disease. The compounds of formula (I) to (XIII) are especially usefulfor nonalcoholic simple fatty liver, nonalcoholic steatohepatitis, non-alcoholic steatohepatitis-induced cirrhosis, ulcerative colitis, Crohn's disease, chronic obstructive Pulmonary diseases, asthma,idiopathic pulmonary fibrosis, cystic fibrosis, allergic rhinitis, diabetic nephropathy, diabetic cardiomyopathy, diabetic ulcers, and autosomal dominant polycystic kidney disease. A pharmaceutical composition for preventing and treating the AMPK-mediated diseases of the present invention comprises a therapeutically effective amount of the compounds of the formula (I) to (XIII) or a pharmaceutically acceptable salt or a solvate thereof as an active ingredient and a pharmaceutically acceptable excipient.
Owner:CHINA PHARM UNIV
Pentacyclic triterpenoid cyclodextrin clathrate compound proliposome and preparation method thereof
ActiveCN102871848ALess irritatingEasy to useCosmetic preparationsBody powdersCholesterolBetulonic acid
Owner:西安雅芝生物科技有限公司
Bearberry type pentacyclic triterpenes amino acid derivates, method for preparing same and pharmaceutical use thereof
InactiveCN101337984AOrganic active ingredientsMetabolism disorderPentacyclic TriterpenesAmino acid derivative
The invention relates to the field of natural drug and medicinal chemistry, in particular to ursane-type pentacyclic triterpenoid amino acid derivatives (I), and the preparation method and the medicinal application thereof. The compounds have effect on inhibiting glycogen phosphorylase, and can be used for preparing drugs for resisting diabetes, cerebral ischemia, cardiovascular diseases, hyperlipemia, obesity, atherosclerosis and tumor. The invention also relates to the preparation method of the compounds and drug preparations containing the compounds.
Owner:CHINA PHARM UNIV
Caffeoyl substituted pentacyclic triterpenoid derivatives and purpose thereof
InactiveCN103342729AImprove neurobehavioral functionReduce brain damageOrganic active ingredientsNervous disorderInjury brainNeuroethology
The invention belongs to the technical field of medicine, and concretely relates to caffeoyl substituted pentacyclic triterpenoid derivatives as shown in a formula I and a purpose thereof in preparing medicaments or health products for preventing and treating brain injury and / or neurological dysfunction and / or cognitive dysfunction caused by cerebral ischemia, hypoglycemia and cerebral anoxia. Experiments verify that the derivatives is capable of protecting nerve cells under conditions of hypoglycemia and hypoxia, can substantially improve neurological damage induced by cerebral ischemia, and thus is expected to be developed as medicaments for preventing and treating the brain injury caused by the cerebral ischemia, the hypoglycemia and the cerebral anoxia as well as improving corresponding neuroethology functions.
Owner:SHANGHAI INST OF MATERIA MEDICA CHINESE ACAD OF SCI
Use of pentacyclic triterpene saponin compound
The usage of a pentacyclic triterpenoid saponins compound relates to the filed of medicines, in particular to a pentacyclic triterpenoid saponins compound for preparing lipid-lowering medicines. The pentacyclic triterpenoid saponins refers to the compound in the right formula: R is H or Beta-D-glucosyl; the structural formula of Beta-D-glucosyl is the right formula.
Owner:安士制药(中山)有限公司
Pentacyclic triterpenoid compound and application of plant extract containing same
InactiveCN102552279ALittle side effectsLow costOrganic active ingredientsDigestive systemSide effectTreatment effect
The invention discloses a pentacyclic triterpenoid compound shown in a formula A or B and an application of a plant extract containing the pentacyclic triterpenoid compound in the preparation of a drug for resisting hepatitis virus C. The pentacyclic triterpenoid compound has the advantages of good treatment effect, low cost and less side effects; and the invention provides a new way for the treatment of the hepatitis C virus. In the formula A, R1 is H, OH or glucoside; R2 is H, OH or glucoside; R3 is CH3, CH2OH or glucoside; R4 is CH3, CH2OH or glucoside; R5 is CH3, COOH or glucoside. In the formula B, R1' is H, OH or glucoside; R2' is H, OH or glucoside; R3' is CH3, CH2OH or glucoside; R4' is CH3, CH2OH or glucoside; R5' is H or OH; R6' is H or CH3; T7' is H or CH3; R8' is H or OH; and R9' is CH3, COOH or glucoside. The formula A and the formula B are shown in the description.
Owner:SHANGHAI INST OF PHARMA IND +1
Application of ilexsaponin compound
InactiveCN102499926AOrganic active ingredientsCardiovascular disorderMyocardial ischemia/hypoxiaMedicine
The invention relates to application of an ilexsaponin compound, in particular to application of a pentacyclic triterpenoid ilexsaponin compound to medicines for preparing cardiovascular diseases caused by myocardial ischemia and anoxia, and belongs to the field of medicines. The ilexsaponin compound is shown by a formula as the specification, wherein R is H or beta-D-glucose, and a structural formula of the beta-D-glucose is shown in the specification.
Owner:刘国樵
Pentacyclic triterpene compound and its preparation method, its pharmaceutical composition and purpose thereof
ActiveCN104910239AOvercome defects such as gallbladder toxicityRich sourcesOrganic active ingredientsMetabolism disorderTriterpenePentacyclic triterpenoid
The present invention relates to a pentacyclic triterpenoid compound represented by general formula (I) and preparation method thereof, pharmaceutical composition comprising the compound, uses of the compound in preparation of drugs for treating type 2 diebetes, and uses of the compound in treating type 2 diebetes.
Owner:SHANGHAI INST OF MATERIA MEDICA CHINESE ACAD OF SCI
Amino acid conjugate prodrug of pentacyclic triterpenoid and medical application thereof
The invention provides a conjugate formed by pentacyclic triterpenoid and amino acid through an ester bond or an urethane bond of the formula I and the formula II, wherein R1 is hydrogen, a methyl, an isopropyl, an isobutyl, a 2-methylpropyl or a benzyl; X is H2 or O; R2 is H, CH3 or COOH; R3 is CH3 or COOH; and R4 is H or CH3.
Owner:BEIJING MEIBEITA DRUG RES
Application of adopting aspirin conjugate with antitumor activity as drug carrier or molecular probe carrier
InactiveCN106420664AHas anticancer effectStrong cytotoxicityPowder deliveryOrganic active ingredientsSolubilityCytotoxicity
The invention discloses application of adopting an aspirin conjugate with the antitumor activity as a drug carrier or a molecular probe carrier. The aspirin conjugate is the conjugate of aspirin and a hydroxyl-containing pentacyclic triterpenoid or amino-containing anti-cancer drugs. According to the application, nanoparticles are formed for an entrapment drug or molecular probe of the aspirin conjugate. The problem of water solubility of multiple drugs is solved, the conjugate has the antitumor activity and does not have large cytotoxicity when as the carrier, the entrapment drug can achieve the better curative effect, and the entrapment molecular probe can achieve integration of diagnosis and treatment.
Owner:FUZHOU UNIV
18 alpha-glycyrrhetinic o-phthalate, and preparation and use thereof
InactiveCN101486751AAvoid damageConvenient treatmentOrganic active ingredientsAntipyreticAcid derivativeFormate
The invention relates to an 18Alpha-glycyrrhetinic acid o-phthalate, a method for preparing the 18Alpha-glycyrrhetinic acid o-phthalate and the application thereof in drugs. The invention aims at providing an 18Alpha-glycyrrhetinic acid o-phthalate which has safe use, strong pharmacological activity, and fast effect, and a method for preparing the 18Alpha-glycyrrhetinic acid o-phthalate; and the method has the advantages of simple process, and high product quality and yield. The technical proposal provided by the invention is as follows: the 18Alpha-glycyrrhetinic acid o-phthalate is characterized by being a pentacyclic triterpenoid derivative of o-phthalic acid which has the chemical name of 3-(1-carboxy-2-oxidation phenoxy)-11-O-18Alpha-oleanane-12-ene-29-formate, the molecular weight of 618.8, and the molecular formula of C38H 50O7 question mark R.
Owner:HANGHZOU HOSPITAL OF TRADITIONAL CHINESE MEDICINE
Use of szechuan melandium root pentacyclic triterpenoid saponin compound in preparation of drug for reducing blood sugar
ActiveCN103599117AGood antidiabetic activityLower blood sugarOrganic active ingredientsMetabolism disorderMedicineBlood sugar
Owner:王学勇 +1
Polysubstitution hydrogenated naphthalene compounds, producing method and uses of the same
The present invention belongs to the field of organic chemistry and relates to a multi-substituted hydrogenated naphthalene compound, the preparation methods and uses. Specifically, the present invention relates to a chiral multi-substituted ten-hydrogen and / or eight-hydrogen naphthalene compound, the synthetic method and uses. The present invention aims to provide a chiral multi-substituted ten-hydrogen and / or eight-hydrogen naphthalene compound; the oleanane-type or usu-type five-ring triterpenoid compound is used as a raw material for preparing the compound. The multi-substituted ten-hydrogen and / or eight-hydrogen naphthalene compound of the present invention can be used for synthesis of drugs or spices containing multi-hydrogen naphthalene fragments and the analogues. The method of the present invention is simple and easy, low in cost, high in production rate, and can realize industrialization.
Owner:CHENGDU INST OF BIOLOGY CHINESE ACAD OF S
23-Substituted Derivatives of Lupane-type Pentacyclic Triterpenoids
InactiveUS20100144688A1Inhibit cell proliferationReduce usageBiocideOrganic active ingredientsGlioblastomaTriterpene
The present invention comprises small molecule inhibitors of cell proliferative conditions, in particular cancer and conditions associated with cancer. For example, associated malignancies include ovarian cancer, cervical cancer, breast cancer, colorectal cancer, and glioblastomas, among others. Accordingly, the compounds of the present invention are useful for treating, preventing, and / or inhibiting these diseases. Thus, the present invention also comprises pharmaceutical formulations comprising the compounds and methods of using the compounds and formulations to inhibit cancer and treat, prevent, or inhibit the foregoing diseases.
Owner:ADVANCED LIFE SCI
Application of pentacyclic triterpene compound and medicine composition
InactiveCN105497041AStrong inhibitory activityOrganic active ingredientsAntineoplastic agentsHalogenHydrogen
The invention discloses application of a pentacyclic triterpene compound and a medicine composition, and further discloses the pentacyclic triterpene compound shown in the formula A or the formula B in the specification, and application of a stereoisomer or a tautomer or pharmaceutically acceptable salt or solvate or polymorph of the pentacyclic triterpene compound in preparing medicine for treating diseases (especially cancer) caused by cell apoptosis or cell damage and a BCL-XL inhibitor. R1, R2, R3, R4, R5, R7, R8, R9, R10 and R11 are independently selected from one of hydroxyl, hydrogen, halogen, COR13, COOR14, C1-C4 alkoxy and C1-C4 alkyl, and R6, R12, R13 and R14 are independently selected from hydrogen or C1-C5 alkyl. The pentacyclic triterpene compound has higher inhibitory activity on binding between BCL-XL and pro-apoptosis protein and has guiding significance on design and research and development of the medicine.
Owner:SHANGHAI INST OF ORGANIC CHEM CHINESE ACAD OF SCI
Applications of five-ring triterpenoid compounds as oxidized squalene cyclase inhibitors
The invention relates to the field of medicines, and particularly relates to applications of five-ring triterpenoid compounds shown as general formulas (I), (II) or (III) or pharmaceutical acceptable salts or esters thereof as oxidized squalene cyclase inhibitors, especially applications in the field of preparation of anti-hypercholesterolemia medicines, anti-hyperlipidemia medicines, medicines for treating heart and cerebral vessels and antitumor medicines, and other fields. The R1 to R6 are defined in the specification.
Owner:CHINA PHARM UNIV
Application of ursane pentacyclic triterpenoids in preparing tumor radiotherapy sensitivity drugs
InactiveCN110680820AOrganic active ingredientsAntineoplastic agentsPentacyclic triterpenoidsProteinase activity
The invention discloses application of ursane pentacyclic triterpenoids in preparing tumor radiotherapy sensitivity drugs. A general molecular formula of the ursane pentacyclic triterpenoids is shownin a formula I. It is found for the first time that the ursane pentacyclic triterpenoids can increase the sensitivity of tumor cells to irradiation by inhibiting the activity of SUMO-specific proteases 1 (SENP1), and the ursane pentacyclic triterpenoids are expected to become new tumor radiotherapy sensitivity drugs. (Please see the description for the formula).
Owner:INST OF RADIATION MEDICINE CHINESE ACADEMY OF MEDICAL SCI
CYP450 gene catalyzing oxidation of C-28 site of amyrin and coding product and application of CYP450 gene
The invention discloses a CYP450 gene IaAO2 catalyzing the oxidation of the C-28 site of amyrin. A protein which catalyzes the oxidation of the C-28 site of amyrin is encoded, and the CYP450 gene IaAO2 can be induced and expressed in engineered strains to catalyze alpha-amyrin and beta-amyrin to be oxidized into ursolic acid and oleanolic acid separately. The nucleotide sequence of the CYP450 geneIaAO2 is as shown in SEQ ID No.1, and the amino acid sequence of the CYP450 gene IaAO2 is as shown in SEQ ID No.2. The invention further discloses an expression vector and host bacterium of the CYP450 gene IaAO2 and application of the CYP450 gene IaAO2 to preparation of triterpenoid compounds, compounds catalyzing the oxidation of the C-28 site of pentacyclic triterpenes and compounds catalyzingthe oxidation of alpha-amyrin and beta-amyrin of pentacyclic triterpenes. The invention further discloses a method for performing homologous gene modification based on the sequence characteristics ofthe gene IaAO2 and a novel gene tIaAO1 obtained by the method. The IaAO2 gene has a shorter nucleotide sequence than a homologous gene, a genetically modified organism can be constructed by using theIaAO2 gene to synthesize a pentacyclic triterpenoid compound with important economic value, and good application prospects are achieved.
Owner:GUANGZHOU UNIVERSITY OF CHINESE MEDICINE
Pentacyclic triterpene compound and application thereof
ActiveCN105418725AImprove securityGood anti-inflammatory activityOrganic active ingredientsAntipyreticHydrogenTriterpene
The invention discloses a pentacyclic triterpene compound and application thereof. The structural general formula of the pentacyclic triterpene compound is shown in the description, wherein the R11 and the R21 independently represent alkyl, hydroxymethyl or their esters, and the R31 and the R41 independently represent hydrogen and alkyl. The pentacyclic triterpene compound has a good anti-inflammatory effect, has the advantages of high efficiency and low toxicity and is expected to develop into a new anti-inflammatory drug and a functional food beneficial to patients suffering from inflammation.
Owner:GUANGDONG PHARMA UNIV
Polysubstituted decahydronaphthalene compound, synthesis method and uses thereof
InactiveCN101367712ASimple methodLow costOrganic compound preparationHydroxy compound preparationAlkaneBond cleavage
The invention belongs to the field of organic chemistry and relates to a polysubstituted decalin compound, and a synthesis method and an application thereof. The structural formula of the polysubstituted decalin compound is shown above. The preparation of the polysubstituted decalin compound includes septs as follows: AB fragment which is obtained by the c-bond cleavage of an oleanane type or an ursolic alkane type pentacyclic triterpenoid compound is treated with different reduction methods to obtain a compound 2 or 3. The polysubstituted decalin compound of the invention is used to synthesize the medicine or the apice and the analogues which contain the structural fragment of the polysubstituted decalin. The invention has the advantages of simplicity, practicability, low cost, high yield and being capable of industrialization.
Owner:CHENGDU INST OF BIOLOGY CHINESE ACAD OF S
11-brominated-12-oleanane type pentacyclic triterpenoid and application thereof
The invention provides an 11-bromo-12-olefin oleanane type pentacyclic triterpene compound, which has a structure as shown in formula (1). The compound has certain inhibition tumor cell growth activity, and can be used to make drugs for preventing and curing tumor diseases. Moreover, the compound has remarkable inhibition action on mice ear tumescence caused by toluene, and can be used to make anti-inflammatory agents. The structural general formula of the 11-bromo-12-olefin oleanane type pentacyclic triterpene compound as shown in formula (1) is shown in the graph.
Owner:ZHEJIANG UNIV
Compound isoglycyrdeuteroside and preparation and usage thereof
The invention discloses pentacyclic triterpenoid compound - iso-glycyrrhizin and the preparation method and the application thereof, with a chemical name 18Alpha-hydro -20Beta-carboxy -11-oxy -oleanane -12-en-3Beta-yl -2-O-Beta-D- pyranyl glucuronic acid. The preparation method is that: enzyme preparation is added into the solution of 18Alpha-glycyrhizic acid in a certain concentration and PH value, then iso-glycyrrhizin is produced in the suitable condition. After the reaction, iso-glycyrrhizin is produced through butanol extraction, macroporous absorption resin separation and purification, recrystalization. The iso-glycyrrhizin disclosed by the invention is a novel compound with obvious sweet performance.
Owner:NANJING UNIV OF TECH
Oleanolic acid derivative and medical application thereof
ActiveCN111205346APotent AMPK agonistic activityHigh activityOrganic active ingredientsNervous disorderPhosphorylationPharmaceutical drug
The invention discloses a pentacyclic triterpenoid novel AMPK agonist oleanolic acid derivative and medical application thereof, and specifically, a compound shown in the formula I or the formula II or a pharmaceutically acceptable salt or an ester or a solvate of the compound can be used for preparing an AMPK agonist with activity of enhancing the phosphorylation level of AMPK and preparing a medicine for preventing or treating AMPK-mediated diseases. The novel pentacyclic triterpenoid compound has remarkable AMPK agonist activity, the activity of the novel pentacyclic triterpenoid compound is remarkably superior to that of an acknowledged AMPK agonist AICAR, and meanwhile the novel pentacyclic triterpenoid compound has better pharmacokinetic properties such as oral bioavailability and the like and very good safety.
Owner:CHINA PHARM UNIV
Derivatives of oleanolic acid and delta-oleanolic acid and medical application thereof
ActiveCN112142818APotent AMPK agonistic activityHigh activityOrganic active ingredientsNervous disorderPhosphorylationPharmaceutical drug
The invention discloses derivatives of oleanolic acid and delta-oleanolic acid as pentacyclic triterpenoid novel AMPK agonists and medical application of the derivatives, and particularly relates to compounds shown as a formula I or a formula II and pharmaceutically acceptable salts or esters or solvates of the compounds. The compounds can be used for preparing AMPK agonists with activity of enhancing the phosphorylation level of AMPK and preparing drugs for preventing or treating AMPK-mediated diseases. The novel pentacyclic triterpenoid compounds disclosed by the invention have remarkable AMPK agonist activity, the activity of the novel pentacyclic triterpenoid compounds are remarkably superior to that of an acknowledged AMPK agonist AICAR, and meanwhile, the novel pentacyclic triterpenoid compounds have pharmacokinetic properties such as better oral bioavailability and the like and very good safety.
Owner:CHINA PHARM UNIV
Application of ilexsaponin in preparation of anti-diabetic medicines
InactiveCN109453182AUnexpected technical effect is goodEsterified saccharide compoundsOrganic active ingredientsDiabetes mellitusAlglucerase
The invention discloses application of pentacyclic triterpenoid saponins in ilex pubescens, namely Ilexsaponin B2, ilexoside A, Ilexsaponin A1,3-O-beta-D-xylopyranosylspathodic acid and flaccidoside I, in preparation of anti-diabetic medicines. Five pentacyclic triterpenoid saponins in ilex pubescens are obtained by large-scale preparation, and the inhibitory activity of the five pentacyclic triterpenoid saponins on alpha-amylase is screened by a large number of experiments. Experimental results show that the five pentacyclic triterpenoid saponins have better inhibitory activity on alpha-glucuronide. Especially, the IC50 of Silverside A and ilexsaponin A1 for alpha-amylase is respectively 0.0849mg / ml and 0.2184mg / ml, thereby obtaining excellent technical effects.
Owner:NANJING UNIVERSITY OF TRADITIONAL CHINESE MEDICINE
Application of A-cyclo trihydroxy substituted pentacyclic triterpene compounds in pharmaceuticals
The invention discloses an application of A-cyclo trihydroxy substituted pentacyclic triterpene compounds in preparation of drugs resistant to tobacco mosaic viruses. The general formula of the compounds is as follows, wherein hydroxyl of C1, C2 and C3 are respectively alpha or beta configuration; R1 and R2 are selected form hydrogen or methyl and R1 is different from R2; R3 is selected from -COOH, -CH2OH, -CHO, -COOR<1>, -CONH2, -CONHR<1> and CONR<1>R<2>; R<1> and R<2> are selected from alkyls of 1-15 carbon atom, substituted or unsubstituted phenyl and substituted or unsubstituted alkyl benzene; a substituted group is selected from halogen, hydroxyl, cyan, amidogen, nitro, sulfydryl or phenyl, acyl, aryl, alkoxy and alkyl containing 1-15 carbons. The compounds have quite high activity in resisting the tobacco mosaic viruses, and good application prospect in the field of pesticides is achieved.
Owner:THE KEY LAB OF CHEM FOR NATURAL PROD OF GUIZHOU PROVINCE & CHINESE ACADEMY OF SCI
Pentacyclic triterpenoid compound, derivatives of pentacyclic triterpenoid compound and applications
ActiveCN108840899AHigh activityHas the prospect of practical clinical applicationOrganic active ingredientsNervous disorderStructural formulaBULK ACTIVE INGREDIENT
The invention provides a pentacyclic triterpenoid compound and derivatives of the pentacyclic triterpenoid compound. The pentacyclic triterpenoid compound and the derivatives of the pentacyclic triterpenoid compound have the significant pseudo nerve growth factor activity and are small-molecular compounds which can pass the blood brain barrier. Thus, through addition of the pentacyclic triterpenoid compound and the derivatives of the pentacyclic triterpenoid compound to pharmaceutically acceptable carriers, drugs for preventing and treating neurodegenerative diseases such as senile dementia (particularly the Alzheimer's disease) and the like can be prepared. Or the pentacyclic triterpenoid compound and the derivatives of the pentacyclic triterpenoid compound are used as active components,food acceptable carriers are added, and food for preventing and treating the neurodegenerative diseases such as the senile dementia and the like can be prepared. The pentacyclic triterpenoid compoundand the derivatives of the pentacyclic triterpenoid compound can also be applied to preparation of food and drugs for preventing and treating the neurodegenerative diseases or improving the cognitiveability and the learning and memory ability. The general structural formula is shown in the Formula I shown in the description.
Owner:ZHEJIANG UNIV
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com